RMD ResMed
FY2025 10-K
ResMed (RMD) filed its fiscal year 2025 10-K annual report with the SEC on Aug 8, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Design, manufacture, and distribute medical devices for respiratory care and sleep apnea management
- • Emphasis on enhanced cybersecurity governance with CISO-led program and annual board updates on risk landscape and incident response
Management Discussion & Analysis
- • Revenue split into Sleep and Breathing Health and Residential Care Software segments; revenue recognized on shipment and service provision respectively
- • Rebates, discounts, and credits reduce Sleep and Breathing Health revenue, estimated via historical data and sales targets quarterly or annually
Risk Factors
- • Delaware corporate law provisions enable issuance of 2.0 million preferred shares without stockholder approval
- • Charter anti-takeover provisions potentially delaying beneficial management changes or acquisition offers
Financial SummaryXBRL
Revenue
$5.1B
Net Income
$1.4B
Gross Margin
59.4%
Operating Margin
32.7%
Net Margin
27.2%
ROE
23.5%
Total Assets
$8.2B
EPS (Diluted)
$9.51
Operating Cash Flow
$1.8B
Source: XBRL data from ResMed FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ResMed
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.